Por Renan Filho · 2026-11-05**Lead**
New evidence is emerging that blockbuster weight‑loss and diabetes medications—such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)—may halt the progression of prediabetes to full‑blown type 2 diabetes. Researchers who re‑examined data from large randomized controlled trials have found that these drugs, originally designed to improve glycemic control and reduce body weight, appear to delay or even prevent the onset of diabetes in individuals with elevated blood sugar levels. If confirmed in dedicated prevention trials, this could reshape clinical practice for millions of Americans at risk.
**Context**
Prediabetes is a condition in which blood glucose levels are higher than normal but not yet high enough to be classified as type 2 diabetes. In the United States, more than one in three adults is estimated to have prediabetes, and the majority are unaware of it. Lifestyle interventions—diet and exercise—have long been the cornerstone of prevention, but adherence is often poor and long‑term success limited. Metformin, an inexpensive generic drug, has also shown modest preventive benefits, yet it is not widely prescribed for this purpose.
GLP‑1 receptor agonists and the dual GIP/GLP‑1 agonist tirzepatide have revolutionized the treatment of obesity and type 2 diabetes. They mimic natural hormones that stimulate insulin secretion, slow gastric emptying, and reduce appetite. Their ability to induce substantial and sustained weight loss—often exceeding 15% of body weight—has made them some of the most prescribed medications in the country. Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide are now household names, with demand far outstripping supply in recent years.
**Analysis**
Why this matters. The progression from prediabetes to diabetes is not inevitable. Approximately 5–10% of people with prediabetes convert to diabetes each year, but the risk can be cut by more than half with effective interventions. If GLP‑1 drugs can achieve that reduction in a real‑world setting, it would represent a major public health victory. Diabetes imposes enormous costs—on individuals through reduced quality of life and complications like kidney failure, blindness, and amputation, and on the healthcare system billions of dollars annually. Preventing even a fraction of those cases would ease the burden on hospitals and insurers.
However, important caveats remain. The drugs are expensive—often more than $1,000 per month without insurance—and insurance coverage for prediabetes is inconsistent. Medicare and many private plans currently restrict coverage to diabetes or obesity, not prediabetes alone. Furthermore, these are lifelong treatments; stopping the medication often leads to weight regain and loss of metabolic benefits. Long‑term safety data beyond four or five years are still being collected. The question of cost‑effectiveness will be central to any policy decisions about expanding their use for prevention.
**Analysis**
Regulatory and guideline shifts may follow. The Food and Drug Administration has already approved semaglutide for cardiovascular risk reduction in overweight or obese adults without diabetes, a decision informed by the SELECT trial. Similar trials examining diabetes prevention as a primary endpoint are underway. If results are positive, the American Diabetes Association and the Endocrine Society may update their clinical practice guidelines to include GLP‑1 drugs as a first‑line option for prediabetes, especially in individuals with obesity or other risk factors. Such a move would echo the recent expansion of bariatric surgery eligibility criteria, where metabolic improvement is now a recognized indication.
Yet access remains the elephant in the room. Even for approved indications, many patients face prior authorizations, high co‑pays, and supply shortages. Manufacturers and policymakers will need to work together to ensure that if these drugs become standard of care for prediabetes, they are not only effective but also affordable and available to those who need them most. The shift from treating diabetes to preventing it would be a paradigm change, and it hinges on the ability of the health system to deliver innovative therapies equitably.
**Fontes**
The information in this article is based on published analyses from major academic medical centers and peer‑reviewed journals, including data from the SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), the SURMOUNT‑1 trial of tirzepatide, and observational studies of real‑world outcomes. Additional context was drawn from the Centers for Disease Control and Prevention’s National Diabetes Statistics Report, the American Diabetes Association’s Standards of Medical Care, and the FDA’s product labeling for Ozempic, Wegovy, Mounjaro, and Zepbound. No specific unpublished data or proprietary research was used.